Systemic Therapy for Patients With Pancreatic Cancer: Current Approaches and Opportunities for Novel Avenues Toward Precision Medicine

Rüveyda Ayasun(NYU Langone Health), Turçin Saridogan(Hacettepe University), Ola Gaber(Moffitt Cancer Center), İbrahim Halil Şahin(University of Pittsburgh)

Clinical Colorectal Cancer

November 4, 2022

10.1016/j.clcc.2022.11.001

Cited by 36Open Access

Abstract

Related Papers

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

Thierry Conroy, Françoise Desseigne, Marc Ychou et al.|New England Journal of Medicine|2011|7.7k

Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine

Daniel D. Von Hoff, Thomas J. Ervin, Francis P. Arena et al.|New England Journal of Medicine|2013|6.6k

Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial

Andrea Wang‐Gillam, Chung‐Pin Li, G. Bodoky et al.|The Lancet|2015|1.2k

KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer

Andrew M. Waters, Channing J. Der|Cold Spring Harbor Perspectives in Medicine|2017|855

Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer

Daniel V.T. Catenacci, Melissa R. Junttila, Theodore Karrison et al.|Journal of Clinical Oncology|2015|538